

Resource Summary Report

Generated by [NIF](#) on Jul 29, 2026

PE anti-mouse H-2Kb bound to SIINFEKL

RRID:AB_10897938

Type: Antibody

Proper Citation

BioLegend Cat# 141603, RRID:AB_10897938

Antibody Information

URL: http://antibodyregistry.org/AB_10897938

Proper Citation: BioLegend Cat# 141603, RRID:AB_10897938

Target Antigen: H-2Kb bound to SIINFEKL

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse H-2Kb bound to SIINFEKL

Description: This monoclonal targets H-2Kb bound to SIINFEKL

Target Organism: mouse

Clone ID: Clone 25-D1.16

Antibody ID: AB_10897938

Vendor: BioLegend

Catalog Number: 141603

Alternative Catalog Numbers: 141604

Record Creation Time: 20250820T000120+0000

Record Last Update: 20250820T070838+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse H-2Kb bound to SIINFEKL.

No alerts have been found for PE anti-mouse H-2Kb bound to SIINFEKL.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zitti B, et al. (2026) Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity. *Immunity*, 59(1), 161.

Sun J, et al. (2025) Blocking WNT7A Enhances MHC-I Antigen Presentation and Enhances the Effectiveness of Immune Checkpoint Blockade Therapy. *Cancer immunology research*, 13(3), 400.

Zuo Y, et al. (2025) IL-36? armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity. *Cancer cell*.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. *Cell*, 187(26), 7470.

Feng S, et al. (2024) Blockage of L2HGDH-mediated S-2HG catabolism orchestrates macrophage polarization to elicit antitumor immunity. *Cell reports*, 43(6), 114300.

Lai Y, et al. (2024) Dietary elaidic acid boosts tumoral antigen presentation and cancer immunity via ACSL5. *Cell metabolism*, 36(4), 822.

Bugno J, et al. (2024) Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(19), 4450.

Li Q, et al. (2024) Biomineralization-inspired synthesis of autologous cancer vaccines for personalized metallo-immunotherapy. *iScience*, 27(7), 110189.

Herbst CH, et al. (2024) Dendritic cells overcome Cre/Lox induced gene deficiency by siphoning cytosolic material from surrounding cells. *iScience*, 27(3), 109119.

Hori A, et al. (2024) MHC class I-dressing is mediated via phosphatidylserine recognition and is enhanced by polyI:C. *iScience*, 27(5), 109704.

Bayerl F, et al. (2023) Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. *Immunity*, 56(6), 1341.

Meiser P, et al. (2023) A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. *Cancer cell*, 41(8), 1498.

Lu Z, et al. (2022) ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes. *Cell metabolism*, 34(9), 1342.

Anadon CM, et al. (2022) Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. *Cancer cell*, 40(5), 545.

Deak P, et al. (2022) Isolating and targeting a highly active, stochastic dendritic cell subpopulation for improved immune responses. *Cell reports*, 41(5), 111563.

Yin X, et al. (2020) PPAR γ Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction. *Cell reports*, 33(3), 108278.

Xia Y, et al. (2018) The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. *Cell*, 175(4), 1059.